Celldex Therapeutics (NASDAQ:CLDX) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Celldex Therapeutics has received a "sell (D-)" rating from Weiss Ratings, amidst a backdrop of mixed reviews from other analysts.
• The stock has seen a price fluctuation, recently trading at $27.24, while maintaining a market capitalization of $1.81 billion.
• Despite its negative earnings per share of (-$0.85), Celldex Therapeutics is projected to post a negative EPS of -2.48 for the current year based on analyst expectations.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently weighed in on CLDX. Canaccord Genuity Group reissued a "buy" rating and set a $62.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Citigroup reduced their price objective on Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. HC Wainwright dropped their price objective on Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating for the company in a research note on Wednesday, August 20th. Finally, Wells Fargo & Company dropped their price target on Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a research note on Wednesday, August 20th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $46.13.

Celldex Therapeutics Trading Up 3.9%

CLDX traded up $1.02 during trading on Wednesday, reaching $27.24. 1,066,887 shares of the company's stock were exchanged, compared to its average volume of 1,134,951. The firm has a fifty day moving average price of $23.81 and a two-hundred day moving average price of $21.38. Celldex Therapeutics has a one year low of $14.40 and a one year high of $31.66. The stock has a market capitalization of $1.81 billion, a PE ratio of -9.05 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.01. The company had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. Sell-side analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CLDX. GAMMA Investing LLC increased its holdings in Celldex Therapeutics by 6,665.9% in the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 2,933 shares during the last quarter. Rhumbline Advisers lifted its position in Celldex Therapeutics by 6.9% in the first quarter. Rhumbline Advisers now owns 98,266 shares of the biopharmaceutical company's stock valued at $1,784,000 after purchasing an additional 6,327 shares during the period. SG Americas Securities LLC increased its holdings in Celldex Therapeutics by 38.0% in the first quarter. SG Americas Securities LLC now owns 34,884 shares of the biopharmaceutical company's stock valued at $633,000 after buying an additional 9,601 shares in the last quarter. Values First Advisors Inc. increased its stake in shares of Celldex Therapeutics by 3.2% during the 1st quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company's stock worth $550,000 after purchasing an additional 924 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Celldex Therapeutics during the 1st quarter worth approximately $269,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.